Local administration of IFN--producing proliferating myeloid cells (IFN--iPSC-pMCs) inhibited the tumor growth not only at the treatment site (right) but also at the distant site (left). We identified genes with log fold expression change  1 or  1 in untreated versus IFN--iPSC-pMC-treated tumors and iPSC-pMC-treated versus IFN--iPSC-pMC-treated tumors for treatment or distant site, respectively. Of the overlapping genes differentially expressed in IFN--iPSC-pMC-treated mice, 301/671 distant site and 460/928 treated site genes were ISGs, of which 95.3% and 94.7%, respectively, were type I IFN-related. By gene ontology, the up-regulated ISG signatures were enriched for T cell-mediated immune responses, cytolysis, and migration of immune cells associated genes. Collectively, Local administration of IFN--iPSC-pMCs alters the tumor microenvironment and propagates molecular signature associated with type I IFN. SOURCE: Ranmaru Shimoda (shimoda@rhelixa.com) -  Rhelixa, Inc.

Pluto Bioinformatics

GSE126279: Local administration of IFN--iPSC-pMCs alters gene expression profiles in tumor microenvironment.